<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02717923</url>
  </required_header>
  <id_info>
    <org_study_id>TJCC005</org_study_id>
    <nct_id>NCT02717923</nct_id>
  </id_info>
  <brief_title>A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer</brief_title>
  <official_title>Maintenance Treatment With Capecitabine Plus Cetuximab After First-line 5-Fluorouracil-based Chemotherapy Plus Cetuximab for Patients With RAS Wild-type Metastatic Colorectal Cancer: a Single Arm, Open-label, Multi-center Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, multi-center clinical trial to evaluate the efficacy and
      safety of maintenance treatment with capecitabine plus cetuximab after first-line
      5-fluorouracil-based chemotherapy plus cetuximab for patients with RAS wild-type metastatic
      colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival of maintaining treatment（mPFS）</measure>
    <time_frame>5 years</time_frame>
    <description>mPFS defined as time from randomisation to progression after maintenance</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Maintenance Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single arm of maintenance treatment with capecitabine plus cetuximab after first-line 5-fluorouracil based standard chemotherapy plus cetuximab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>maintenance treatment with capecitabine plus cetuximab</intervention_name>
    <description>Using a maintenance treatment strategy of capecitabine plus cetuximab as a treatment option in mCRC after first-line 5-FU-based chemotherapy plus cetuximab</description>
    <arm_group_label>Maintenance Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects has been fully understand this research and volunteered to sign the consent
             form;

          2. Histologically and/or cytologically diagnosed with RAS wild-type metastatic metastatic
             colorectal cancer(Phase IIIc/IV), any other histological type is excluded;

          3. Subjects with stable disease or better after induction treatment with eight to twelve
             2-weekly cycles of 5FU-based standard chemotherapy;

          4. ECOG Performance Status (ECOG PS) ≤1(0-1);

          5. Evident measurable lesion(s) that meets the Response Evaluation Criteria in Solid
             Tumors (RECIST 1.1);

          6. Expected survival＞16 weeks.

        Exclusion Criteria:

          1. Subjects with presence of clinically detectable second primary malignant tumors at the
             enrollment, or other malignant tumors within the last 5 years (excluding adequately
             treated skin basal cell carcinoma or carcinoma in situ of cervix);

          2. Clinical refractory diseases(including uncontrolled epilepsy),and affect survivor;

          3. Central Nervous System (CNS) metastatic disease or prior cerebral metastasis;

          4. Researchers think that the subjects exist any clinical or laboratory abnormalities or
             compliance issues and not suitable to participate in this clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xianglin Yuan, Professional</last_name>
    <phone>13667241722</phone>
    <email>yxl@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ben Zhao, Master</last_name>
    <phone>15071206621</phone>
    <email>zhaoben0609@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianglin Yuan, Professional</last_name>
      <phone>13667241722</phone>
      <email>yxl@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ben Zhao, Master</last_name>
      <phone>15071206621</phone>
      <email>zhaoben0609@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, Tol J, Braun HJ, Nieboer P, van der Hoeven JJ, Haasjes JG, Jansen RL, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJ, Koopman M. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015 May 9;385(9980):1843-52. doi: 10.1016/S0140-6736(14)62004-3. Epub 2015 Apr 7.</citation>
    <PMID>25862517</PMID>
  </reference>
  <reference>
    <citation>Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2015 Oct;16(13):1355-69. doi: 10.1016/S1470-2045(15)00042-X. Epub 2015 Sep 8. Erratum in: Lancet Oncol. 2015 Dec;16(16):e589.</citation>
    <PMID>26361971</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2016</study_first_submitted>
  <study_first_submitted_qc>March 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2016</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Xianglin Yuan</investigator_full_name>
    <investigator_title>Professor, Chief physician</investigator_title>
  </responsible_party>
  <keyword>metastatic colorectal cancer</keyword>
  <keyword>maintenance treatment</keyword>
  <keyword>cetuximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

